Citations

Showing 10 of 108152 citations.

Elevated holo‐transcobalamin in Gaucher disease type II: A case report
Basgalupp, Suélen Porto , Donis, Karina Carvalho , Siebert, Marina , Artigalás, Osvaldo , Pinto, Louise L. de Camargo, Behringer, Sidney, Spiekerkoetter, Ute , Hannibal, Luciana , E Vairo, Filippo Pinto, Hannibal, Luciana , Vairo, Filippo Pinto e , Schwartz, Ida Vanessa Döederlein

Mayo Clinic

American Journal of Medical Genetics Part A | May 25, 2021 | Volume: 185 | Issue: 8 | Pages: 2471-2476

10.1002/ajmg.a.62252 | PMID 34031990 Get It

AbstractGaucher disease (GD), one of the most common lysosomal disorders, is caused by deficiency of β‐glucocerebrosidase. Based on the presence and severity of neurological complications, GD is classified into types I, II (the most severe form), and III. Abnormalities in systemic markers of vitamin B12 (B12) metabolism have been reported in GD type I patients, suggesting a higher prevalence of B12 deficiency in these patients. A 2‐month‐old male with GD type II was admitted to the hospital presenting jaundice, hepatosplenomegaly, and ichthyosis. At admission, cholestasis and ascites, abnormal liver function enzymes, prolonged prothrombin time, and high levels of B12 were confirmed. Analysis of biomarkers of B12 status revealed elevated B12 and holo‐transcobalamin (holo‐TC) levels. The B12 profile found in our patient is the opposite to what is described for GD type I patients. Holo‐TC may increase in inflammatory states or due to liver diseases. In GD, the accumulation of glucocerebroside may be a trigger that initiates a systemic inflammatory reaction, characterized by macrophage activation. We suggest higher levels of holo‐TC could be associated with a more severe (neuronopathic) GD, and be a biomarker of GD type II.
Coronary Heart Disease Risk Associated with Primary Isolated Hypertriglyceridemia; a Population‐Based Study
Saadatagah, Seyedmohammad , Pasha, Ahmed K. , Alhalabi, Lubna, Sandhyavenu, Harigopal , Wood‐Wentz, Christina M. , Bailey, Kent R. , Kullo, Iftikhar J. , Farwati, Medhat , Wood-Wentz, Christina M, Kullo, Iftikhar J , Sandhyavenu, Harigopal , Smith, Carin Y.

Mayo Clinic

Journal of the American Heart Association | May 25, 2021 | Volume: 10 | Issue: 11 | Pages: No page available

10.1161/jaha.120.019343 | PMID 34032140 Get It

Background Hypertriglyceridemia is associated with increased risk of coronary heart disease but the association is often attributed to concomitant metabolic abnormalities. We investigated the epidemiology of primary isolated hypertriglyceridemia (PIH) and associated cardiovascular risk in a population‐based setting. Methods and Results We identified adults with at least one triglyceride level ≥500 mg/dL between 1998 and 2015 in Olmsted County, Minnesota. We also identified age‐ and sex‐matched controls with triglyceride levels <150 mg/dL. There were 3329 individuals with elevated triglyceride levels; after excluding those with concomitant hypercholesterolemia, a secondary cause of high triglycerides, age <18 years or an incomplete record, 517 patients (49.4±14.0 years, 72.0% men) had PIH (triglyceride 627.6±183.6 mg/dL). The age‐ and sex‐adjusted prevalence of PIH in adults was 0.80% (0.72–0.87); the diagnosis was recorded in 60%, 46% were on a lipid‐lowering medication for primary prevention and a triglyceride level <150 mg/dL was achieved in 24.1%. The association of PIH with coronary heart disease was attenuated but remained significant after adjustment for demographic, socioeconomic, and conventional cardiovascular risk factors (hazard ratio [HR], 1.53; 95% CI, 1.06‐2.20; P = 0.022). There was no statistically significant association between PIH and cerebrovascular disease (HR, 1.06; 95% CI, 0.65‐1.73, P = 0.813), peripheral artery disease (HR, 1.27; 95% CI, 0.43‐3.75; P = 0.668), or the composite end point of all 3 (HR, 1.28; 95% CI, 0.92‐1.80; P =0.148) in adjusted models. Conclusions PIH was associated with incident coronary heart disease events (although there was attenuation after adjustment for conventional risk factors), supporting a causal role for triglycerides in coronary heart disease. The condition is relatively prevalent but awareness and control are low.
Fungal Infection in Lung Transplantation
Kennedy, Cassie C. , Pennington, Kelly M. , Kennedy, Cassie C , Beam, Elena , Razonable, Raymund R.

Mayo Clinic

Seminars in Respiratory and Critical Care Medicine | May 24, 2021 | Volume: 42 | Issue: 03 | Pages: 471-482

10.1055/s-0041-1729173 | PMID 34030208 Get It

AbstractInvasive fungal infections threaten lung transplant outcomes with high associated morbidity and mortality. Pharmacologic prophylaxis may be key to prevent posttransplant invasive fungal infections, but cost, adverse effects, and absorption issues are barriers to effective prophylaxis. Trends in fungal infection diagnostic strategies utilize molecular diagnostic methodologies to complement traditional histopathology and culture techniques. While lung transplant recipients are susceptible to a variety of fungal pathogens, Candida spp. and Aspergillus spp. infections remain the most common. With emerging resistant organisms and multiple novel antifungal agents in the research pipeline, it is likely that treatment strategies will continue to evolve.
Mycobacteria: Selection of Transplant Candidates and Post–lung Transplant Outcomes
Friedman, Daniel , Doucette, Karen , Friedman, Daniel Z P, Friedman, Daniel Z P

Mayo Clinic

Seminars in Respiratory and Critical Care Medicine | May 24, 2021 | Volume: 42 | Issue: 03 | Pages: 460-470

10.1055/s-0041-1727250 | PMID 34030207 Get It

AbstractMycobacterium is a large, clinically relevant bacterial genus made up of the agents of tuberculosis and leprosy and hundreds of species of saprophytic nontuberculous mycobacteria (NTM). Pathogenicity, clinical presentation, epidemiology, and antimicrobial susceptibilities are exceptionally diverse between species. Patients with end-stage lung disease and recipients of lung transplants are at a higher risk of developing NTM colonization and disease and of severe manifestations and outcomes of tuberculosis. Data from the past three decades have increased our knowledge of these infections in lung transplant recipients. Still, there are knowledge gaps to be addressed to further our understanding of risk factors and optimal treatments for mycobacterial infections in this population.
Acute Hypertensive Response in Patients With Acute Intracerebral Hemorrhage
Hawkes, Maximiliano A. , Rabinstein, Alejandro A.

Mayo Clinic

Neurology | May 24, 2021 | Volume: 97 | Issue: 7 | Pages: 316-329

10.1212/wnl.0000000000012276 | PMID 34031208 Get It

Propofol, Ketamine, and Etomidate as Induction Agents for Intubation and Outcomes in Critically Ill Patients: A Retrospective Cohort Study
Wan, Chun, Hanson, Andrew C. , Schulte, Phillip J. , Dong, Yue , Bauer, Philippe R.

Mayo Clinic

Critical Care Explorations | May 24, 2021 | Volume: 3 | Issue: 5 | Pages: e0435

10.1097/cce.0000000000000435 | PMID 34046636 Get It

IMPORTANCE: Propofol, ketamine, and etomidate are common anesthetic agents for induction of anesthesia in the ICU. The choice between these agents is complex and may not depend solely upon severity of illness. OBJECTIVES: To evaluate the association between the administration of propofol, ketamine, and etomidate and ICU, hospital mortality, and length of stay. DESIGN, SETTING, AND PARTICIPANTS: Retrospective single-center cohort study. ICUs in a tertiary medical center, between January 01, 2012, and December 31, 2017. Critically ill adult patients given a single IV anesthetic for intubation. MAIN OUTCOME AND MEASURES: Primary outcomes were ICU and hospital mortality. Secondary outcomes were ICU- and hospital-free days through 28 days. An inverse probability of treatment weighed approach was used. The propensity score was estimated using a generalized logit model as a function of patient characteristics, admission source, ICU type, readmission status, length of ICU stays prior to intubation, and acute physiology score. Mortality outcomes were assessed with weighted logistic regression and -free days assessed by weighted linear regression with Bonferroni correction for pairwise comparisons. RESULTS: Of 2,673 patients, 36% received propofol, 30% ketamine and 34% etomidate. Overall ICU and hospital mortality were 19% and 29%, respectively. Patients given ketamine had higher odds of ICU mortality (1.45; [95% CI, 1.07–1.94]; p = 0.015) and patients given etomidate had higher odds of ICU mortality (1.87; 1.40–2.49; p < 0.001), hospital mortality (1.43; 1.09–1.86; p = 0.009), and less ICU-free days (–2.10; –3.21 to –1.00; p < 0.001) than those given propofol. Patients given ketamine and etomidate had similar odds of hospital mortality (1.06; 0.80–1.42; p = 0.761) and similar hospital-free days (0.30; –0.81 to 1.40; p = 0.600). CONCLUSIONS AND RELEVANCE: Compared with ketamine and etomidate, propofol was associated with better outcome in critically ill patients undergoing anesthesia for intubation. Even after adjusting for severity of illness prior to intubation, residual confounders cannot be excluded.
Teriparatide Treatment Increases Hounsfield Units in the Thoracic Spine, Lumbar Spine, Sacrum, and Ilium Out of Proportion to the Cervical Spine
Mikula, Anthony L. , Jeor, Jeffery D. St. , Naylor, Ryan M. , Bernatz, James T. , Patel, Nitesh P. , Fogelson, Jeremy L. , Sebastian, Arjun S. , Freedman, Brett A. , Currier, Bradford L. , Bydon, Mohamad , Kennel, Kurt A. , Yaszemski, Michael J. , Anderson, Paul A. , Elder, Benjamin D. , Bernatz, James T. , Larson, A. Noelle , Nassr, Ahmad

Mayo Clinic

Clinical Spine Surgery | May 24, 2021 | Volume: 34 | Issue: 7 | Pages: E370-E376

10.1097/bsd.0000000000001203 | PMID 34029261 Get It

Study Design: This was a retrospective chart review. Objective: The objective of this study was to compare the effect of teriparatide on Hounsfield Units (HU) in the cervical spine, thoracic spine, lumbar spine, sacrum, and pelvis. Second, to correlate HU changes at each spinal level with bone mineral density (BMD) on dual-energy x-ray absorptiometry (DXA). Summary of Background Data: HU represent a method to estimate BMD and can be used either separately or in conjunction with BMD from DXA. Materials and Methods: A retrospective chart review included patients who had been treated with at least 6 months of teriparatide. HU were measured in the vertebral bodies of the cervical, thoracic, and lumbosacral spine and iliac crests. Lumbar and femoral neck BMD as measured on DXA was collected when available. Results: One hundred twenty-five patients were identified for analysis with an average age of 67 years who underwent a mean (±SD) of 22±8 months of teriparatide therapy. HU improvement in the cervical spine was 11% (P=0.19), 25% in the thoracic spine (P=0.002), 23% in the lumbar spine (P=0.027), 17% in the sacrum (P=0.11), and 29% in the iliac crests (P=0.09). Lumbar HU correlated better than cervical HU with BMD as measured on DXA. Conclusions: Teriparatide increased average HU in the thoracolumbar spine to a proportionally greater extent than the cervical spine. The cervical spine had a higher baseline starting HU than the thoracolumbar spine. Lumbar HU correlated better than cervical and thoracic HU with BMD as measured on DXA.
Flap Reconstruction for Treatment of Pediatric Linear Scleroderma
Yan, María , Stans, Anthony A. , Moran, Steven L.

Mayo Clinic

Annals of Plastic Surgery | May 24, 2021 | Volume: 87 | Issue: 5 | Pages: 533-536

10.1097/sap.0000000000002887 | PMID 34699432 Get It

Background Linear scleroderma is a rare connective tissue disease characterized by thickening of the skin due to excess collagen deposit. It is the most frequent type of localized scleroderma in the pediatric population (40%–70%), and it usually affects the extremities and head. Linear scleroderma can cause growth disturbances, extremity length discrepancy, and debilitating joint contractures. The aim of this study was to describe the surgical outcomes of microsurgical flap reconstruction of linear scleroderma in the pediatric population. Methods A retrospective review of all children with linear scleroderma was performed at our institution. Patients less than 18 years of age with clinical diagnosis of linear scleroderma and who underwent microsurgical flap reconstruction for correction of their scleroderma were included. Fat grafting procedures were excluded. Patient demographics and surgical outcomes were collected. Results A total 7 patients underwent microsurgical flap reconstruction for treatment of their linear scleroderma producing debilitating soft tissue contractures and preventing ambulation or elbow extension. Six patients had scleroderma involving the lower extremity and 1 involving the upper extremity. Three anterolateral thigh and 4 latissimus dorsi flaps were performed. The median age at surgery was 7 years (Q1–Q3, 5–11), and the median body mass index was 21.3 kg/m2 (Q1–Q3, 16.5–22.1). The median follow-up was 121.1 months (Q1–Q3, 43.2–187.4). All flaps survived, and no donor site complications were reported. Perioperative complications included wound infection that required debridement (n = 1), immediate postoperative bleeding requiring surgical intervention (n = 1), intraoperative venous congestion (n = 1), and scleroderma recurrence outside the flap (n = 2). When comparing anterolateral thigh and latissimus dorsi flaps, there was no statistically significant difference in the development of surgical complications, number of surgical revisions per patient [median, 4 (Q1–Q3, 4–7) vs 2.5 (Q1–Q3, 1.3, 3), P = 0.0916], or unplanned surgical interventions [median, 0 (Q1–Q3, 0–1) vs 1 (Q1–Q3, 0–1), P = 0.7228]. The reconstruction was successful in improving range of motion in 6 patients, 5 of which reached full weight-bearing. However, all patients had residual limb deformity, and 4 had remaining extremity length discrepancy. Conclusions Microsurgical flaps are a good option for functional improvement of severe pediatric linear scleroderma affecting the extremities. However, residual limb deformity is common, and patients are often required to undergo additional surgical revisions.
Procedural Trends in Medicare Reimbursement and Utilization for Breast Reconstruction
Thornburg, Danielle A. , Chow, Nathan , Haglin, Jack M. , Kruger, Erwin A., Rebecca, Alanna M. , Casey, William J., Teven, Chad M. , Chow, Nathan A, Haglin, Jack, Kruger, Erwin, Chow, Nathan A , Gupta, Nikita

Mayo Clinic

Annals of Plastic Surgery | May 24, 2021 | Volume: 89 | Issue: 1 | Pages: 28-33

10.1097/sap.0000000000002830 | PMID 35234409 Get It

Purpose Development of appropriate reimbursement models for breast reconstruction in the United States requires an understanding of relevant economic trends. The purpose of this study is to evaluate longitudinal patterns in Medicare reimbursement for frequently performed breast reconstruction procedures between 2000 and 2019. Methods Reimbursement data for 15 commonly performed breast reconstruction procedures were analyzed using the Centers for Medicare & Medicaid Services Physician Fee Schedule Look-Up Tool for each Current Procedural Terminology code. By utilizing changes to the US consumer price index, monetary data were adjusted for inflation to 2019 US dollars. Inflation-adjusted trends were used to calculate average annual and total percentage changes in reimbursement over time. Results From 2000 to 2019, average adjusted reimbursement for all procedures fell by 13.32%. All procedures demonstrated a negative adjusted reimbursement rate other than immediate insertion of breast prosthesis, which increased by 55.37%. The largest mean decrease was observed in breast reconstruction with other technique (−28.63%), followed by single pedicle transverse rectus abdominis myocutaneous flap (−26.02%), single pedicle transverse rectus abdominis myocutaneous flap with microvascular anastomosis (−23.33%), latissimus dorsi flap (−19.65%), and free flap reconstruction (−19.36%). Conclusions There has been a steady yet substantial decline in Medicare reimbursement for the majority of breast reconstruction procedures over the last 20 years. Given increasing medical costs and the financial uncertainty of the US health care system, an understanding of Medicare reimbursement trends is vital for policymakers, administrators, and physicians to develop agreeable reimbursement models that facilitate growth and economic vitality of breast reconstruction in the United States.
Teaching Video NeuroImages: Periodic Alternating Nystagmus in Paraneoplastic KLHL11 Rhomboencephalitis
Bohm, Parker , Eggenberger, Eric , Dubey, Divyanshu , Kim, Hyun Woo , López‐Chiriboga, A. Sebastian , Eggenberger, Eric R, Dubey, Divyanshu

Mayo Clinic

Neurology | May 24, 2021 | Volume: 96 | Issue: 21 | Pages: No page available

10.1212/wnl.0000000000011711 | PMID 33589533 Get It